Last reviewed · How we verify

ACT01 — Competitive Intelligence Brief

ACT01 (ACT01) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: S1P receptor modulator. Area: Multiple Sclerosis.

phase 2 S1P receptor modulator S1P1 Multiple Sclerosis Small molecule Live · refreshed every 30 min

Target snapshot

ACT01 (ACT01) — Promius Pharma, LLC. ACT01 is a small molecule that targets the S1P receptor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ACT01 TARGET ACT01 Promius Pharma, LLC phase 2 S1P receptor modulator S1P1
FTY720 FTY720 Novartis Pharmaceuticals marketed Sphingosine-1-phosphate receptor modulator; Immunomodulator Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5)
fingolimob (FTY) fingolimob (FTY) University Hospital, Clermont-Ferrand marketed Sphingosine-1-phosphate receptor modulator S1P1 receptor (sphingosine-1-phosphate receptor 1)
Group S+T Group S+T Huazhong University of Science and Technology marketed S1P receptor modulator S1P1
Placebo matching fingolimod Placebo matching fingolimod Biogen phase 3 Sphingosine-1-phosphate receptor modulator S1P1, S1P3, S1P4, S1P5 (sphingosine-1-phosphate receptors)
NU100 NU100 Nuron Biotech Inc. phase 3 S1P1 receptor modulator S1P1
Placebo to ozanimod Placebo to ozanimod Celgene phase 3 Sphingosine-1-phosphate (S1P) receptor modulator S1P1 and S1P5 receptors

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (S1P receptor modulator class)

  1. Promius Pharma, LLC · 2 drugs in this class
  2. Nobelpharma · 2 drugs in this class
  3. Bausch & Lomb Incorporated · 1 drug in this class
  4. Biogen · 1 drug in this class
  5. Celgene · 1 drug in this class
  6. Geropharm · 1 drug in this class
  7. GlaxoSmithKline · 1 drug in this class
  8. Hoffmann-La Roche · 1 drug in this class
  9. Huazhong University of Science and Technology · 1 drug in this class
  10. Otsuka Pharmaceutical Co., Ltd. · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ACT01 — Competitive Intelligence Brief. https://druglandscape.com/ci/act01. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: